APOPTOTIC CELL-DEATH DURING TREATMENT OF LEUKEMIAS

被引:83
作者
LI, X [1 ]
GONG, JP [1 ]
FELDMAN, E [1 ]
SEITER, K [1 ]
TRAGANOS, F [1 ]
DARZYNKIEWICZ, Z [1 ]
机构
[1] NEW YORK MED COLL,INST CANC RES,ELMSFORD,NY 10523
关键词
PROGRAMMED CELL DEATH; DNA TOPOISOMERASE INHIBITORS; PROGNOSIS; CHEMOTHERAPY; ARA-C; TAXOL;
D O I
10.3109/10428199409052678
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The apoptosis-associated DNA strand breaks were detected in situ, in individual leukemic cells in peripheral blood and bone marrow of over 110 patients with different types of leukemia (ALL, AML, CML in blastic crisis, APL), prior to and during routine chemotherapy. The DNA strand breaks were labeled with digoxigenin- or biotin-conjugated dUTP in the reaction catalyzed by exogenous terminal deoxynucleotidyl transferase, and the cells, counterstained for DNA, were analyzed by bivariate flow cytometry. The proportion of cells with DNA strand breaks prior to therapy, most likely reflecting spontaneous apoptosis, varied from 0.1 to 16%, but in the large majority of cases was below 3%. Administration of drugs of different classes, which included DNA topoisomerase I (Topotecan) and II (mitoxantrone, VP-16) inhibitors, antimetabolite (ara-C) or microtubule poison (Taxol), all triggered the appearance of cells with extensive DNA breakage, typical of apoptosis, to up to 80%. The peak of the response, measured as maximal percent of cells with DNA strand breaks, which varied between individual patients by as much as factor 10, was generally seen between 8 to 24 h after the initial administration of DNA topoisomerase inhibitors, and somewhat later (48-72 h) during the response to Taxol or ara-C. Thus, the data show that the response to treatment with a variety of drugs, in terms of induction of apoptosis, can be conveniently measured by the present method. The prognostic value of the apoptotic index, before, as well as during treatment, is being estimated for each type of leukemia, in the ongoing prospective studies.
引用
收藏
页码:65 / 70
页数:6
相关论文
共 17 条
[1]
Arends M.J., Morris R.G., Wyllie A.H., Apoptosis: The role of endonuclease, American Journal of Pathology, 136, 5, pp. 593-608, (1990)
[2]
Wyllie A.H., Apoplosis and the regulation of cell numbers in normal and neoplastic tissues: an overview, Cancer and Metastasis Reviews, 11, pp. 95-103, (1992)
[3]
Compton M.M., A biochemical hallmark of apoptosis: lnternucleosomal degradation of the genome, Cancer and Metastasis Reviews, 11, pp. 105-119, (1992)
[4]
Tsujimoto Y., Ikegaki N., Croce C.M., Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma, Oncogene, 2, pp. 3-7, (1987)
[5]
Kerr K.M., Lamb D., A suggested explanation for the paradoxically slow rate of growth of basal carcinomas that contain numerous mitotic figures, Journal of Pathology, 107, pp. 41-50, (1984)
[6]
Askew D.A., Ashmun R.A., Simmonds B.C., Cleveland J.L., Constitutive c-myc and IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis, Oncogene, 6, pp. 1915-1922, (1991)
[7]
Evan G.I., Wyllie A.H., Gilbert C.S., Littlewood T.D., Land H., Brooks M., Waters C.M., Penn L.Z., Hancock D.C., Induction of apoptosis in fibroblasts by c-myc protein, Cell, 69, pp. 119-128, (1992)
[8]
Wang Y., Ramquist T., Szekely L., Axelson H., Klein G., Wiman K.G., Reconstitution of wild-type p53 expression triggers apoptosis in a p53 negative v-myc retrovirus-induced T-cell lymphoma line, Cell Growth Differentiation, 4, pp. 467-473, (1993)
[9]
Kaufmann S.H., Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs. A cautionary note, Cancer Research, 49, pp. 5870-5878, (1989)
[10]
Hickmann J.A., Apoptosis induced by anticancer drugs, Cancer and Metastasis Reviews, 11, pp. 121-139, (1992)